In contrast, a patient with loss of <i>BAP1</i> was linked to a CD8+ T-cell enriched tumor microenvironment, classified as spatially immune enriched and responded long-term to subsequent immune checkpoint inhibition and tyrosine kinase inhibition therapy.<h4>Conclusion</h4>These observations provide a rationale for integrated genomic and spatial immune profiling in BTC, which will require further prospective validation. This evidence concerns the gene CD8A and neoplasm.